Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Maryland
Clinical trial register · United States · industry-sponsored

Clinical Trials in Maryland, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 139 Florida 113 Illinois 72 New York 62 Texas 53
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca10 Verastem, Inc.2 Aktis Oncology, Inc.1 Nimbus Saturn, Inc.1 Daiichi Sankyo Co., Ltd.1
State
California139 Florida113 Illinois72 New York62 Texas53
All 48 states
Target enrolment
to

Trials with a site in Maryland

30 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Illinois, Maryland, Minnesota, Missouri, Nebraska
2026-09-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
90
Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota
2025-03-30
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Recruiting
Teligene US
Phase 2
99
California, Georgia, Kentucky, Maryland, North Carolina, Texas
2022-09-01
Recruiting
InSightec
Phase 3
30
Arizona, California, Florida, Maryland, North Carolina, Oregon, Rhode Island, Virginia
2022-08-12
Recruiting
BioNTech SE
Phase 1
320
Kentucky, Maryland, Ohio, Texas, Virginia
2022-06-17
Recruiting
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
Verastem, Inc.
Phase 1/2
153
Colorado, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2022-04-12
Active, closed
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2022-02-18
Active, closed
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
180
California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York
2022-02-15
Recruiting
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT05627960Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
A&G Pharmaceutical Inc.
Phase 1
77
Maryland
2022-02-14
Active, closed
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin
Synthekine
Phase 1/2
364
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts
2022-01-25
Active, closed
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
DrugPembrolizumab
Nimbus Saturn, Inc.
Phase 1/2
106
Arizona, Connecticut, District of Columbia, Florida, Kentucky, Maryland, Michigan, Minnesota
2021-11-05
Active, closed
AstraZeneca
Phase 3
98
Maryland, Massachusetts
2021-09-12
Active, closed
Daiichi Sankyo
Phase 3
605
Arizona, California, Florida, Illinois, Indiana, Kentucky, Louisiana, Maryland
2020-12-21
Active, closed
Candel Therapeutics, Inc.
Phase 2
90
Arizona, Connecticut, Illinois, Maryland, Minnesota, New York, Ohio, Pennsylvania
2020-10-13
Active, closed
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
DrugPembrolizumab
Precision Biologics, Inc
Phase 1/2
121
Maryland, Virginia
2019-01-18
Active, closed
AstraZeneca
Phase 3
825
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2018-12-06
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
DrugDato-DXd
Daiichi Sankyo Co., Ltd.
Phase 1
890
California, District of Columbia, Georgia, Maryland, Massachusetts, New York, Tennessee, Texas
2018-01-31
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
AstraZeneca
Phase 2
528
California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, New York, Pennsylvania
2017-12-18
Active, closed
Janssen Research & Development, LLC
Phase 1
751
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2016-05-24
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/maryland

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Maryland that also match the filters currently applied.

How many clinical trials are recruiting in Maryland?

15 of the 30 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Maryland), 30 studies
PhaseStudiesRecruitingShare
Phase 310433.3%
Phase 17423.3%
Phase 27423.3%
Phase 1/25216.7%
Phase 4113.3%

Most active sponsors

Lead sponsors with the most studies (Maryland)
Lead sponsorStudiesRecruiting
AstraZeneca103
Verastem, Inc.21
A&G Pharmaceutical Inc.11
Aktis Oncology, Inc.11
BioNTech SE11
Bristol-Myers Squibb11
Candel Therapeutics, Inc.10
Daiichi Sankyo10
Daiichi Sankyo Co., Ltd.10
InSightec11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.